The Superbug Fight Needs a Better Business Model
The current pipeline for new antibiotics is “on the verge of collapse” within the next four to eight years—and a key reason is that antibiotic makers can’t stay in business.
Examining the complex mix of health, politics, economics, culture, and environment, and related obstacles to health
Explore the latest public health research and insights about International Health.
The current pipeline for new antibiotics is “on the verge of collapse” within the next four to eight years—and a key reason is that antibiotic makers can’t stay in business.
Looking for prominent public health experts in the field of International Health? They’re here at the Bloomberg School of Public Health.
Judd L. Walson, MD, MPH, is an infectious disease physician and epidemiologist who works to improve child survival, growth, and development in low- and middle-income settings.
Melissa A. Marx, PhD ‘02, MPH ’98, evaluates maternal, child, and infectious disease programs, and has led response efforts for outbreaks including SARS, Ebola, and COVID-19.